Inflammatory Bowel Disease News and Research

Latest Inflammatory Bowel Disease News and Research

Book on pediatric IBD launched

Chronic inflammatory bowel disease (IBD) encompasses Crohn's disease, ulcerative colitis and indeterminate colitis. The distinct phenotype in pediatric and adolescent patients and the difference from adult IBD make early-onset IBD a unique subgroup requiring specific therapeutic considerations. In this book, leading experts from the USA, Europe and Israel present new data on the genetics, epidemiology, pathology and pathogenesis of pediatric IBD. Imaging and endoscopy in the diagnosis of IBD are also discussed.

19 Nov 2009

Johns Hopkins University to create a Human Proteome Chip using Arrayit's technology

Arrayit Corporation announced today that the new High Throughput Biology Center at Johns Hopkins University School of Medicine in Baltimore Maryland purchased Arrayit's proprietary technology to create a Human Proteome Chip to discover biomarkers for autoimmune diseases including rheumatoid arthritis, inflammatory bowel disease, autoimmune hepatitis (first identified by Dr. Zhu), lupus, and others.

18 Nov 2009

4SC raises funds for further development of its current product pipeline

4SC AG, a drug discovery and development company, today announced the successful completion of a capital increase, after the Management Board, with the approval of the Supervisory Board, passed a resolution to authorise an increase of share capital on 23 October, 2009.

16 Nov 2009

Self-care tips for hemorrhoids from Mayo Clinic

By about age 50, more than half of adults have dealt with hemorrhoids. The November issue of Mayo Clinic Health Letter covers home treatments that can relieve symptoms of this common and embarrassing problem.

16 Nov 2009

Research team identifies five new gene regions that raise the risk of childhood-onset IBD

In the largest, most comprehensive genetic analysis of childhood-onset inflammatory bowel disease (IBD), an international research team has identified five new gene regions, including one involved in a biological pathway that helps drive the painful inflammation of the digestive tract that characterizes the disease.

16 Nov 2009

Ore Pharmaceutical Holdings reports financial results and provides operational updates for third quarter 2009

Ore Pharmaceutical Holdings Inc. today reported financial results and provided an operational update for the third quarter ended September 30, 2009.

13 Nov 2009

Cequent Pharmaceuticals proposes the first test of an orally administered RNA interference drug in humans

Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, has announced that it has filed its first IND (investigational new drug) application with the U.S. Food and Drug Administration (FDA).

12 Nov 2009

Pharmos announces financial results for the third quarter of 2009

Pharmos Corporation today reported financial results for the third quarter and nine-month period ended September 30, 2009.

12 Nov 2009

William D. Carey Award for Boston University School of Medicine professor

Francis A. Farraye, MD, MSc, FACG, FASGE, a professor of medicine at Boston University School of Medicine (BUSM) and clinical director in the Gastroenterology Section at Boston Medical Center (BMC) recently received the William D. Carey Award from the American College of Gastroenterology (ACG). The award is reserved for an exceptional individual who has served the Board and the College with distinction.

5 Nov 2009

GI and hepatology societies take initiative to evaluate the current medical school curriculum

Due to the increasing complexities of treating digestive diseases, allowing gastroenterological (GI) trainee physicians the opportunity to develop enhanced abilities and experiences in specific disease areas or procedures will be a great benefit to patients, according to a "Report of the Multisociety Task Force on GI Training."

4 Nov 2009

Online resource to illustrate genetic networks in common autoimmune diseases published

Currently, 5-8% of the U.S. population is afflicted with an autoimmune disease (www.niaid.nih.gov). Many of these are chronic and require life-long care. Moreover, different autoimmune diseases aggregate within a single family, suggesting they are caused by disruptions in common biological pathways.

30 Oct 2009

AMT inks agreement with Progenika Biopharma for development of LPLchip

Amsterdam Molecular Therapeutics (AMT) and Progenika Biopharma announced today that the companies have entered into a development and commercialization agreement for LPLchip(TM), a diagnostic tool to rapidly diagnose patients with complete and partial lipoprotein lipase deficiency (LPLD). AMT has developed Glybera(R) as a gene therapy for patients with this disease.

29 Oct 2009

U.S. Department of Defense funds Rush University Medical Center for gastrointestinal microorganism research

The human body contains billions of microorganisms, and microbial cells found in the human gut are estimated to outnumber human cells by ten-to-one in healthy adults. However, little is known about the ways in which these minute life forms influence health and disease.

28 Oct 2009

New data from CIMZIA WELCOME trial to be presented at the ACG meeting

According to new results from the WELCOME trial, exploratory data analyzing the impact of treatment with CIMZIA(®) (certolizumab pegol) - the only PEGylated anti-TNF (alpha) (Tumor Necrosis Factor alpha) - administered either every two weeks or every four weeks, showed that the majority of Crohn's disease patients in both dosing groups experienced no hospitalizations and surgical procedures during the course of the 26-week study.

28 Oct 2009

Controlled trial in UC meets primary endpoint of non- inferiority for reducing ulcerative colitis

Results from the largest prospective controlled ulcerative colitis (UC) trial conducted to date, called the QD dosing investigation for efficacy IN UC maintenance (QDIEM), found that once-daily dosing of Asacol(R) (mesalamine) delayed-release 400 mg tablets at 1.6-2.4 g/day was comparable to twice-daily dosing for the maintenance of remission in patients with UC.

28 Oct 2009

Treatment with TYSABRI reduces the rate of hospitalization in Crohn’s patients

Elan Corporation, plc and Biogen Idec today announced data showing that treatment with TYSABRI® (natalizumab) significantly reduced the rate of hospitalization compared with placebo in patients with moderate–to–severe Crohn’s disease during both induction and maintenance treatment.

28 Oct 2009

Positive results from Phase II clinical trial of INT-747 announced

Intercept Pharmaceuticals, Inc., today announced positive results from a 165 patient, placebo controlled, double-blind Phase II clinical trial of INT-747 in patients with primary biliary cirrhosis (PBC).

27 Oct 2009

Comprehensive, risk-based screening guidelines for breast, cervical and colorectal cancers

Drawing on years of experience in cancer research and patient care, The University of Texas M. D. Anderson Cancer Center released today the most comprehensive, risk-based screening guidelines publicly available to date for breast, cervical and colorectal cancers.

27 Oct 2009

Detecting the cause of occult gastrointestinal bleeding with the PillCam SB video capsule demonstrated

Given Imaging Ltd. today announced that new data presented at the American College of Gastroenterology (ACG) 2009 Conference show that by visualizing the small bowel with the PillCam® SB video capsule, physicians can detect the cause of occult gastrointestinal bleeding (OGIB) and adapt how they manage and treat these patients.

27 Oct 2009

New data from efficacy study of CIMZIA in Crohn's disease patients presented

New data from an open-label extension study evaluating the long-term safety and efficacy of CIMZIA® (certolizumab pegol) in moderate to severe Crohn's disease patients demonstrate that 82 percent of patients actively treated with CIMZIA - the only PEGylated anti-TNF-alpha (Tumor Necrosis Factor alpha) - remained in long-term remission without dose escalation up to 3.5 years.

27 Oct 2009

Inflammatory Bowel Disease News and Research

Latest Inflammatory Bowel Disease News and Research

Book on pediatric IBD launched

Johns Hopkins University to create a Human Proteome Chip using Arrayit's technology

4SC raises funds for further development of its current product pipeline

Self-care tips for hemorrhoids from Mayo Clinic

Research team identifies five new gene regions that raise the risk of childhood-onset IBD

Ore Pharmaceutical Holdings reports financial results and provides operational updates for third quarter 2009

Cequent Pharmaceuticals proposes the first test of an orally administered RNA interference drug in humans

Pharmos announces financial results for the third quarter of 2009

William D. Carey Award for Boston University School of Medicine professor

GI and hepatology societies take initiative to evaluate the current medical school curriculum

Online resource to illustrate genetic networks in common autoimmune diseases published

AMT inks agreement with Progenika Biopharma for development of LPLchip

U.S. Department of Defense funds Rush University Medical Center for gastrointestinal microorganism research

New data from CIMZIA WELCOME trial to be presented at the ACG meeting

Controlled trial in UC meets primary endpoint of non- inferiority for reducing ulcerative colitis

Treatment with TYSABRI reduces the rate of hospitalization in Crohn’s patients

Positive results from Phase II clinical trial of INT-747 announced

Comprehensive, risk-based screening guidelines for breast, cervical and colorectal cancers

Detecting the cause of occult gastrointestinal bleeding with the PillCam SB video capsule demonstrated

New data from efficacy study of CIMZIA in Crohn's disease patients presented

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Inflammatory Bowel Disease News and Research

Latest Inflammatory Bowel Disease News and Research

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Newsletters you may be interested in